

Curriculum Vitae

*** Within 3 pages**

	Name in Full	Travis Edward Grotz, MD, MS
	Country	United States
	Affiliation	Mayo Clinic, Rochester, Minnesota, USA
	Email	grotz.travis@mayo.edu

Educational Background

2002-2004 Saint John's University - B.A.
 2004-2008 Creighton University School of Medicine - M.D.
 2008-2015 Mayo Clinic - General Surgery Residency
 2011-2013 Mayo Clinic - Clinical Investigator / Immunology Research Fellowship
 2015-2017 MD Anderson Cancer Center - Complex General Surgical Oncology Fellowship
 2021-2023 Mayo Clinic Graduate School - M.S., Clinical and Translational Science

Professional Career

2017-2020 Senior Associate Consultant, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic
 2020-present Consultant, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic
 2018-2023 Assistant Professor of Surgery, Mayo Clinic College of Medicine and Science
 2023-present Associate Professor of Surgery, Mayo Clinic College of Medicine and Science
 2024-present Program Director, Complex General Surgical Oncology Fellowship, Mayo Clinic
 2020-present Co-Chair, Multidisciplinary Gastroesophageal Cancer Tumor Board, Mayo Clinic
 2022-present American Board of Surgery - Certifying Board (Oral) Examiner

Research Field

Gastric and gastroesophageal junction cancer; peritoneal surface malignancies; cytoreductive surgery and HIPEC; regional cancer therapies; immunotherapy and tumor immune biology; minimally invasive/robotic oncologic surgery; translational research and clinical trials in gastrointestinal malignancies.

Papers, Books, etc. presented or published by your name

(topic title, year, conference name or presenting books)

Peer-reviewed publications: 171 total (through August 2026)

GI, peritoneal surface and pancreas-related publications

1. Preoperative Tumor Index Predicts Peritoneal Recurrence after Perioperative Chemotherapy and Resection of Gastric Cancer. J Gastrointest Surg. 2026.
2. NSQIP Outcomes for Open and Minimally Invasive Gastrectomy for Malignancy. J Surg Oncol. 2026.
3. Secondary Cytoreductive Surgery +/- Hyperthermic Intraperitoneal Chemotherapy for Recurrent Colorectal Cancer Peritoneal Metastases. Ann Surg Oncol. 2026.
4. Epigenomic profiling links IGF2 overexpression to anthracycline resistance in colorectal cancer organoids. JCI Insight. 2026.
5. Perioperative hemoglobin trajectories and transient hemodilution during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Biomol Biomed. 2026.
6. Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma. Ann Surg Oncol. 2026.
7. De-Escalating Surgery for 1-2 cm Appendiceal Neuroendocrine Tumors: A North American Multi-Center Analysis. J Surg Oncol. 2026.



8. Mesothelioma: Pleural, Version 3.2026. JNCCN. 2026.
9. Perioperative Outcomes from a Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial. Ann Surg Oncol. 2026.
10. Lymphadenectomy Considerations Beyond Standard Gastrectomy. Ann Surg Oncol. 2026.
11. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. J Surg Oncol. 2026.
12. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Ann Surg Oncol. 2026.
13. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement. Ann Surg Oncol. 2026.
14. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement. Ann Surg Oncol. 2026.
15. Consensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies. Ann Surg Oncol. 2026.
16. Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases. Ann Surg Oncol. 2026.
17. Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases. Ann Surg Oncol. 2026.
18. Long-term quality of life, financial toxicity, and decision regret following therapeutic and prophylactic gastrectomy for cancer. Gastric Cancer. 2026.
19. Transpacific multicenter collaborative study of minimally invasive proximal gastrectomy vs. minimally invasive total gastrectomy for proximal gastric and gastroesophageal junction cancers: 3-month follow-up results. Surg Endosc. 2025.
20. Incidence and risk of gastric neuroendocrine tumors and adenocarcinoma in patients with atrophic gastritis/pernicious anemia. J Gastrointest Surg. 2025.
21. Immune Checkpoint Inhibitors for Mismatch Repair-Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic. JCO Precis Oncol. 2025.
22. Gastric neuroendocrine tumors arising from chronic proton pump inhibitor use: characteristics and outcomes of a fourth subtype. J Gastrointest Surg. 2025.
23. Modified Proximal Gastrectomy and D2 Lymphadenectomy Is an Oncologically Sound Operation for Locally Advanced Proximal and GEJ Adenocarcinoma. Cancers (Basel). 2025.
24. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer. 2025.
25. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025.
26. Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases. Cancer. 2025.
27. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer. 2025.
28. Mucinous Appendiceal Neoplasms and Pseudomyxoma Peritonei: Imaging Features and Current Therapies. Radiographics. 2025.
29. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Ann Surg Oncol. 2025.
30. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Curr Oncol. 2025.
31. Updates in the multidisciplinary approach for resectable gastroesophageal adenocarcinoma and peritoneal-limited disease. JNCCN Journal of the National Comprehensive Cancer Network. 2025.
32. Total neoadjuvant therapy (tnt) improves completion rates of intended therapy and oncologic outcomes in locally advanced gastric cancer. Surgical Oncology Insight. 2025.
33. The Emerging Role of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pancreatic Cancer. J Surg Oncol. 2024.
34. Risk stratification of surveillance for low-grade appendiceal mucinous neoplasms. J Gastrointest Surg. 2024.
35. Gastric polyposis and risk of gastric cancer in patients with familial adenomatous polyposis. J Gastrointest Surg. 2024.
36. Cytoreduction and Hyperthermic Intrathoracic Chemotherapy for Metastatic Pseudomyxoma Peritonei. Ann Thorac Surg Short Rep. 2024.
37. Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum. Ann Surg Oncol. 2024.
38. Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative. Ann Surg Oncol. 2024.
39. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Ann Surg Oncol. 2024.
40. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol. 2024.
41. Long term outcomes associated with the use of perioperative systemic chemotherapy on low grade appendiceal mucinous neoplasms with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Front Oncol. 2024.
42. Cytoreduction and Hyperthermic Intraperitoneal Paclitaxel and Cisplatin for Gastric Cancer with Peritoneal Metastasis. Ann Surg Oncol. 2024.
43. Prediction of Early Recurrence Following CRS/HIPEC in Patients With Disseminated Appendiceal Cancer. J Surg Res. 2023.
44. Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection. J Surg Oncol. 2023.
45. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2023.
46. Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy. Ann Surg Oncol. 2023.
47. Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-institutional Analysis. Ann Surg Oncol. 2023.
48. Trans-pacific multicenter collaborative study of minimally invasive proximal versus total gastrectomy for proximal gastric and gastroesophageal junction cancers. BMC Surg. 2023.



49. Principles of Surgical Management of Peritoneal Mesothelioma. J Natl Compr Canc Netw. 2023.
50. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023.
51. Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Pleura Peritoneum. 2023.
52. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. J Am Coll Surg. 2023.
53. Disparities in tyrosine kinase inhibitor use in older patients with gastrointestinal stromal tumors. J Geriatr Oncol 2023 May; 14 (4):101441 Epub 2023 Jan 28 PMID: 36717324 DOI: 10.1016/j.jgo.2023.101441. 2023.
54. Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC. J Surg Oncol. 2023.
55. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative. Ann Surg Oncol. 2023.
56. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. Ann Surg Oncol. 2023.
57. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study. J Gastrointest Surg. 2022.
58. The role of proximal gastrectomy in gastric cancer. Chin Clin Oncol. 2022.
59. Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease? J Surg Res. 2022 Sep; 277:269-278 Epub 2022 May 04 PMID: 35525209 DOI: 10.1016/j.jss.2022.04.007. 2022.
60. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. J Natl Compr Canc Netw. 2022.
61. Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery. JAMA Netw Open. 2022.
62. What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers? Ann Surg Oncol. 2022 Mar 19 [Epub ahead of print] PMID: 35307803 DOI: 10.1245/s10434-022-11472-w. 2022.
63. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2022.
64. Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. J Gastrointest Surg. 2022.
65. Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspiration. Surgery. 2021.
66. The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. J Gastrointest Surg. 2021.
67. Perception versus reality: A National Cohort Analysis of the surgery- first approach for resectable pancreatic cancer. Cancer Med. 2021.
68. Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Ann Surg Oncol. 2021.
69. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinical Trial. J Am Coll Surg. 2021.
70. A national database analysis of acinar cell carcinoma of the pancreas, a histologically, epidemiologically, and biologically distinct entity increasing in incidence Annals of Pancreatic Cancer. 2021 Jul; 4:A105. 2021.
71. Finding the Balance: General Surgery Resident Versus Fellow Training and Exposure in Hepatobiliary and Pancreatic Surgery. J Surg Educ. 2021.
72. Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Curr Treat Options Oncol. 2021.
73. Can cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) be diagnosed in a patient with non-steroidal anti-inflammatory drug exposure? BMJ Case Rep. 2021 Feb 4; 14 (2) Epub 2021 Feb 04 PMID: 33542016 PMCID: PMC7868250 DOI: 10.1136/bcr-2020-238160. 2021.
74. Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. J Cancer Epidemiol. 2021.
75. A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. J Surg Oncol. 2021.
76. The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Ann Surg Oncol. 2020.
77. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol. 2020.
78. Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi- Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol. 2020.
79. CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol. 2020.
80. Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. J Surg Res. 2020.
81. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol. 2020.
82. Emergent pancreatectomy for neoplastic disease: outcomes analysis of 534 ACS-NSQIP patients. BMC Surg. 2020.
83. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020.
84. Preoperative opioid use is associated with increased length of stay after pancreaticoduodenectomy. HPB (Oxford). 2020.

